New Publication in Journal of Translational Oncology
December 2, 2013
Horizon Oncology Research, Inc. in Lafayette, Indiana USA collaborates with Fluxion Biosciences Inc. in South San Francisco, CA to prove the efficacy of their novel microfluidic collection workflow called the IsoFlux System that analyzes circulating tumor cells (CTC). Horizon Oncology Research, Inc designed and executed a pilot study, collecting peripheral blood samples and KRAS mutation status from a cohort of colorectal cancer patients. The microfluidic system and mutation assay proves to provide a complete workflow to track oncogene mutational changes longitudinally with high success rates.
A full article describing the research involved has been published in the Journal of Translational Oncology. See the full publication here.
To learn more about Fluxion Biosciences, Inc. and the IsoFlux System, visit www.fluxionbio.com